Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale

20260 citationsJournal Articlehybrid Open Access

Authors

Zhen Fan · Mitsubishi Corporation (United Kingdom)

Graham Searle · Mitsubishi Corporation (United Kingdom)

Gaia Rizzo · Mitsubishi Corporation (United Kingdom)

Justin M. Albani · Mitsubishi Corporation (United Kingdom)

Patrick Cella · General Electric (Spain)

Robert A. Comley · AbbVie (United States)

Gregory Klein

Abstract

The Centamine scale holds promise for the harmonized quantification of dopaminergic neuronal imaging markers. The Centamine strategy would enable and accelerate clinical trials in Parkinson's disease using dopaminergic imaging outcomes. ANN NEUROL 2026;99:949-963.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Neurotransmitter Receptor Influence on Behavior

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Neurology

Volume 99, Issue 4, pp. 949-963

DOI: 10.1002/ana.78116

Field-Weighted Citation Impact: 0.00